Brief: Mezzion Pharma Announces Positive Data Presented To FDA In Type C Meeting
21/12/2021 19:30
Dec 21 (Reuters) - Mezzion Pharma Co Ltd 140410.KQ :
* MEZZION PHARMA ANNOUNCES POSITIVE DATA PRESENTED TO FDA IN
TYPE
C MEETING
* MEZZION PHARMA CO LTD- NEWLY PRESENTED DATA FROM FUEL
TRIAL IS
STATISTICALLY SIGNIFICANT
* MEZZION PHARMA - NEWLY PRESENTED DATA FROM FUEL TRIAL
SUPPORTS
EFFICACY AND CLINICAL RELEVANCE FOR UDENAFIL TREATMENT OF THIS
VERY LARGE SUBGROUP
* MEZZION PHARMA- FUEL OLE TRIAL DATA BELIEVED TO GIVE
INDEPENDENT CONFIRMATORY EVIDENCE OF REPRODUCIBILITY, DURABILITY
OF EFFICACY FOR LARGE SUBGROUP
Source text for Eikon: ID:nPn7J56Rja
Further company coverage: 140410.KQ
((Reuters.Briefs@thomsonreuters.com))
Recent news on Mezzion Pharma
See all newsBrief: Mezzion Secures Strategic Financing To Support Advancement Of Global Phase 3 Fuel-2 Trial In Fontan Patients
Brief: Mezzion Reports Pre-Ind FDA Feedback On The Development Of Udenafil In Adpkd
Brief: Mezzion Pharmaceuticals Appoints Ridwan Shabsigh As President & Chief Operating Officer
Brief: Mezzion Pharmaceuticals Reaches Key Enrollment Milestone In World's Largest Fontan Clinical Trial
Brief: Mezzion Pharmaceuticals Announces Dr Rahul Rathod As Global Principal Investigator For The Confirmatory Pivotal Phase 3 Trial FUEL-2